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Abstract
This study is based on an expanded access program in which 
511 patients suffering from active refractory rheumatoid arthritis 
(RA) were treated with intravenous infusions of infliximab (3 mg/ 
kg+methotrexate (MTX)) at weeks 0, 2, 6 and every 8 weeks 
thereafter. At week 22, 474 patients were still in follow-up, of 
whom 102 (21.5%), who were not optimally responding to 
treatment, received a dose increase from week 30 onward. W e 
aimed to build a model to discriminate the decision to give a 
dose increase. This decision was based on the treating 
rheumatologist's clinical judgment and therefore can be 
considered as a clinical measure of insufficient response. 
Different single and composite measures at weeks 0, 6, 14 and
22, and their differences over time were taken into account for 
the model building. Ranking of the continuous variables based 
on areas under the curve of receiver-operating characteristic 
(ROC) curve analysis, displayed the momentary DAS28
(Disease Activity Score including a 28-joint count) as the most 
important discriminating variable. Subsequently, we proved that 
the response scores and the changes over time were less 
important than the momentary evaluations to discriminate the 
physician's decision. The final model we thus obtained was a 
model with only slightly better discriminative characteristics than 
the DAS28. Finally, we fitted a discriminant function using the 
single variables of the DAS28. This displayed similar scores and 
coefficients as the DAS28. In conclusion, we evaluated different 
variables and models to discriminate the treating 
rheumatologist's decision to increase the dose of infliximab 
(+MTX), which indicates an insufficient response to infliximab at
3 mg/kg in patients with RA. W e proved that the momentary 
DAS28 score correlates best with this decision and 
demonstrated the robustness of the score and the coefficients 
of the DAS28 in a cohort of RA patients under infliximab therapy.
ACR =  American College of Rheumatology; AUC =  area under the curve; CDAI =  clinical disease activity score; CI =  confidence interval; CRP =  C- 
reactive protein; DAS =  disease activity score; DAS28 =  Disease Activity Score including a 28-joint count; ESR =  erythrocyte sedimentation rate; 
HAQ =  Health Assessment Questionnaire; MTX =  methotrexate; RA =  rheumatoid arthritis; ROC =  receiver-operating characteristic; SDAI =  simpli­
fied disease activity score; SJC =  swollen joint count; SJC28 =  28 swollen joint count; TJC =  tender joint count; TJC28 =  28 tender joint count; VAS 
=  visual analogue scale; VAS =  Visual Analogue Score. R1063
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Introduction
Rheumatoid arthritis (RA) is a complex disease w ith a broad 
spectrum  of manifestations that requires an early intensive 
therapy in order to avoid jo int destruction and physical d isabil­
ity. In order to measure the effect of therapy in daily practice 
and in clinical trials, many variables are recorded and different 
com posite indices have been proposed to measure the 
remaining disease activity or the response to treatment. Those 
variables may cover items such as patient self-reported ques­
tionnaires, physician's scores including different jo int scores, 
and serum markers of system ic inflammation.
Infliximab, in combination w ith methotrexate (MTX), is a highly 
effective therapy for a majority of RA patients. A fte r an induc­
tion scheme at weeks 0, 2 and 6, the indicated dose of this 
therapy is 3 m g/kg every 8 weeks, although the ATTRACT trial 
suggested that a higher dose of 10 m g/kg every 8 weeks or a 
shorter perfusion interval may add benefit [1-3].
The present study is based on an expanded-access program 
in which patients suffering from active refractory RA were 
treated w ith intravenous infusions of infliximab (3 m g/kg +  
MTX) at weeks 0, 2, 6 and every 8 weeks thereafter. A t week 
22, patients not optimally responding to treatm ent could 
receive a dose increase of 100 mg (1 vial) per infusion from 
week 30 onwards [4]. The effect of dose escalation for the 
patients of this cohort has been discussed previously [4]. The 
decision to increase the dose was based on the treating rheu­
m atologist's clinical judgm ent and can be considered as a 
measure of insufficient response to infliximab. It m ight be ques­
tioned which variables can be measured to best evaluate the 
effect of therapy and remaining disease activity in daily prac­
tice (and in clinical trials). The aim of the present analyses was 
to evaluate whether the decision to increase the dose could be 
reflected by using single variables or com posite indices, alone 
or together in a model. W e also wanted to evaluate whether 
this decision was mainly based on differences over time or on 
momentary disease activity.
Table  1
F orm ulae  to  ca lcu la te  th e  d iffe re n t DAS and SDAI score
Methods
Study population
A total of 511 patients, suffering from active refractory RA [5], 
were treated w ith intravenous infusions of infliximab (3 mg/kg) 
at weeks 0, 2, 6 and every 8 weeks thereafter in combination 
w ith MTX (a minimal dose of 15 mg/kg was recommended). 
Between week 0 and week 22, 37 patients dropped out for 
the fo llow ing reasons: 16 patients stopped due to side effects 
(four infusion reactions, five infections, one malignancy, one 
pancytopenia, five disease-related com plications), 12 patients 
stopped fo r w ithdrawal of consent and 9 patients stopped for 
protocol violation. O f the remaining 47 4  patients, 102 (22% ) 
patients, who were not optimally responding to treatment 
according to the treating rheum atologist's opinion, received a 
dose increase of 100 mg (1 vial) per infusion from week 30 on. 
Throughout the first 22 weeks, dosage of MTX, steroids and 
non-steroidal anti-inflammatory drugs remained unchanged.
Evaluated variables
W hen designing the model, we took the fo llow ing single vari­
ables into account at weeks 0, 6, 14 and 22: 28  and 66 /68  
swollen/tender jo int counts, erythrocyte sedimentation rate 
(ESR; mm/h), C-reactive protein (CRP; mg/l), Health Assess­
ment Questionnaire (HAQ; 0 -3 ), physician's global assess­
ment of disease activity (visual analogue scale (VAS); 0 -1 0 0  
mm), patient's global assessment of disease activity (VAS 0 ­
100 mm), patient's assessment of pain (VAS 0 -1 0 0  mm), 
patient's assessment of fatigue (VAS 0 -1 0 0  mm) and all sub­
scales of the SF-36 questionnaire (0 -1 0 0  points) [6]. DAS28 
(Disease Activity Score including a 28-jo int count) [7] and 
other com posite scores such as sim plified disease activity 
index (SDAI), clinical disease activity index (CDAI) [8,9] and 
the alternative D AS28 scores [10 ,11] (Table 1) were calcu­
lated after data collection so that the treating rheumatologist 
was unaware of the exact values of those com posite scores. 
Also, differences over time and the D A S 28 response (no, 
moderate or good) and the A C R  (American College of Rheu­
matology) response (no /20 /50 ) were com puted [12,13].
Score Formula AUC (95% CI) Sens at 95%  spec, % (95% CI)
DAS28
DAS28-3
DAS28-CRP
DAS28-CRP-3
SDAI
CDAI
0.56*sqrt(28TJC) + 0.28*sqrt(28SJC) + 0.70*ln(ESR) + 0.014*pt global VAS 
[0.56*sqrt(28TJC) + 0.28*sqrt(28SJC) + 0.70*ln(ESR)]*1.08 + 0.16 
0.56*sqrt(28TJC) + 0.28*sqrt(28SJC) + 0.36*ln(CRP+1) + G.G14* pt global VAS + 0.96 
[0.56*sqrt(28TJC) + 0.28*sqrt(28SJC) + 0.36*ln(CRP+1)] * 1.10 + 1.15 
28TJC + 28SJC + CRP/10 + pt global VAS/10 + phys global VAS/10 
28TJC + 28SJC + pt global VAS/10 + phys global VAS/10
0.840 (0.791-0.889) 
0.815 (0.763-0.868) 
0.829 (0.782-0.876) 
0.806 (0.755-0.858) 
0.824 (0.776-0.873) 
0.821 (0.772-0.870)
42.5 (36.9-48.1)
37.8 (32.3-43.3)
35.8 (30.4-41.2)
28.9 (23.8-33.9)
40.7 (35.1-46.2)
37.8 (32.3-43.2)
DAS28-3 and DAS28-CRP-3 are the DAS28 and DAS28-CRP scores calculated without the patient's global disease activity VAS. AUC, area 
under the curve; CDAI, clinical disease activity score; CRP, C-reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation rate; 
phys, physician; pt, patient; SDAI, simplified disease activity score; SJC28, 28 swollen joint count; TJC28, 28 tender joint count; VAS, Visual 
Analogue Scale.
R1G64
A va ila b le  o n lin e  http://arthritis-research.eom/content/7/5/R1063
Statistics
W e opted to use only statistical m ethods that are available in 
a classical statistical package (SPSS 12.0; SPSS, Inc, C h i­
cago, IL, USA) or could be com puted manually. W hen needed, 
the continuous variables were normalized (by taking the 
square root of the jo int counts and the natural logarithm of 
CRP and ESR). Robustness of the discrim inant analyses and 
logistic regressions was confirmed by the use of a random 
train and test set. Missing values were handled by pairwise 
com plete case analysis. This means that a case w ith no m iss­
ing values fo r a group of variables is included in the analysis of 
that group of variables. The case may have missing values for 
variables used in other analyses. Confidence intervals (95%  
CI) fo r sensitivity or specific ity were calculated based on the 
method proposed by Harper [14]. The areas under the curves 
(AUCs) of receiver operating characteristic (ROC) curves 
were calculated. A  higher A U C  indicates that a single variable 
has better discrim inative characteristics. A  statistical test to 
compare AU C s of two variables tested on the same popula­
tion has been described by Hanley [15]. Continuous and ca t­
egorical variables were com pared by adapting the cut-off of 
the continuous variables to the same specific ity level as the 
categorical variable so that sensitivities could be evaluated 
and com pared [16]. The selection and comparison of variables 
by curve analysis was performed since this method gives a 
valid ranking of variables and does not (in contrast to ranking 
m ethods based on p  values) depend on the number of sub­
jects available for that specific  variable [1 7]. In order to find the 
true maximal model and to avoid sticking at a local maximal 
model, we used different strategies for the construction of the 
final model: binary logistic regressions and discrim inant 
analyses were performed w ith the default options of SPSS 
12.0 and stepw ise construction of models was performed by 
conditional forward and backward elimination fo r logistic 
regression and by W ilk 's  lambda for discrim inant analysis 
using the strategy described by Hosmer and Lem eshow [18].
Ethics
All patients signed informed consent. This study was approved 
by the local eth ics committees.
Results
Ranking of continuous variables
In order to select the most im portant variables that correlate 
w ith the decision to give a dose increase at week 22, we cal­
culated the A U C  of R O C  curve analysis fo r all continuous var­
iables and ranked them based on this A U C  [17]. S ince 
crossing over of R O C  curves may affect the diagnostic prop­
erties of a variable w ithout changing the AUC, we also ranked 
the variables based on sensitivity levels by adapting the cut-off 
to a given preset specific ity level of 95%  [16].
Both ranking m ethods displayed that the D A S 28 score at 
week 22 had the highest ability to discrim inate the physician's 
decision to give a dose increase. Table 2 displays the 10 most
important variables ranked by A U C  of R O C  curve analysis and 
by the sensitivity at the 95%  specific ity level. Using the method 
described by Hanley [15], we found that there was a s ignifi­
cant difference in A U C  between the two first ranked parame­
ters: D AS28 at week 22 and the 28 tender jo int count at week 
22 (AUC =  0 .840 versus 0.797, p  =  0.02). Additionally, most 
variables were ranked in such a way that each variable was 
represented first by its measure at week 22 before it was rep­
resented by a measure at another week.
Evaluation of the response scores
To evaluate categorical scores, we adapted the cut-off of the 
variable w ith the highest ranking (DAS28 at week 22) to the 
specific ity of the categorical score and compared the sensitiv­
ities [16]. For the decision to give a dose increase, AC R  
response not reaching the A C R 20 criterion ('no AC R  
response') had a sensitivity of 69 .6%  (95%  CI: 6 5 .2 -7 4 .0 ) 
and a specific ity of 64 .2%  (95%  CI: 5 9 .6 -6 8 .8 ). W hen we 
adapted the cut-off of the D A S 28 at week 22 to a specific ity 
of 64 .2%  (DAS28 =  4.01), we obtained a sensitivity of 80 .0%
(95%  CI: 75 .2 -84 .7 ). 'No D AS 28 response' had a sensitivity 
of 46 .7%  (95%  CI: 4 0 .8 -5 2 .6 ) and a specific ity of 83 .3%
(95%  CI: 78 .9 -87 .7 ). W hen we adapted the cut-off of the 
D AS28 to a specific ity of 83 .3%  (DAS28 =  4.77), we 
obtained a sensitivity of 67 .5%  (95%  CI: 6 1 .9 -7 3 .1 ). Sim ilar 
results were obtained when looking at the A C R 50 and the 
good D AS28 response criterion (Table 3 ).
Additionally, we fitted a logistic regression model w ith the 
decision to give a dose increase as a dependent variable and 
D AS28 at week 22, D AS28 response and AC R  response as 
categorical covariates. These analyses retained D A S28 at 
week 22 as the only significant covariate in the model (data not 
shown).
Effects of change of scores over time on the physician’s 
decision
To evaluate the effect of differences over time, we plotted the 
means of the most important normalized continuous variables 
over time (Fig. 1). The plot of the variable w ith the highest rank­
ing (DAS28) shows that patients who get a dose increase 
have a (significantly) higher disease activity at baseline and, 
after an initial decrease of disease activity, regain disease 
activity from week 6 on. To evaluate this, we calculated differ­
ences in D AS28 scores between baseline and week 22 (delta 
D AS28 0 -2 2 ) , and between week 6 and week 22 (delta 
D AS28 6 -2 2 ). Indeed, patients who get a dose increase 
regain some disease activity between week 6 and week 22 
(mean delta D AS28 6 -2 2 : -0.4 versus +0.4, p  <  0.001), 
which is reflected in a smaller decrease of disease activity 
between baseline, and week 22 (mean delta D AS 28 0-22: -2 
versus -1, p  <  0.001). However, the A U C  of the R O C  curve of 
delta D AS28 0 -2 2  was 0 .725  (95%  CI: 0 .6 5 9 -0 .7 9 0 ) and 
the A U C  for delta D AS28 6 -2 2  was 0 .672 (95%  CI: 0 .5 90 ­
0.754), which is much lower than the A U C  of the momentary
R1065
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Table  2
V ariab les  w ith  the  h ighes t rank ing  based on ROC curve AUC and s e n s itiv it ie s  a t 95% sp e c ific ity
AUC 95% CI of AUC
D AS28w22 0.840 0.791-0.889
28 TJC w22 0.797 0.744-0.850
Physician global VAS w22 0.786 0.736-0.836
Patient pain VAS w22 0.764 0.71-0.814
DAS28w14 0.750 0.685-0.815
Patient disease activity VAS w22 0.750 0.689-0.802
66TJC w22 0.740 0.689-0.791
28TJC w14 0.721 0.662-0.780
66SJC w22 0.717 0.660-0.774
ESR w22 0.716 0.654-0.779
Sensitivity (%) at 95% specificity level 95% CI of sensitivity
DAS28 w22 42.5 36.9-48.1
Physician global VAS w22 32.7 28.4-37.0
28SJC w22 29.8 24.7-34.9
Patient pain VAS w22 26.8 22.7-30.9
66SJC w22 24.5 20.6-28.4
ESR w22 24.1 19.7-28.5
66SJC w14 23.0 18.6-27.4
CRP w22 21.3 17.3-25.3
Patient disease activity VAS w22 20.4 16.6-4.2
DAS28w14 20.3 15.3-25.3
AUC, area under the curve; TJC, tender joint count; SJC, swollen joint count; ESR, erythrocyte sedimentation rate; CI, confidence interval; CRP, 
C-reactive protein; w, week.
Tab le  3
S e n s itiv ity  and s p e c ific ity  o f th e  response scores com pared w ith  DAS28 se t a t equal sp e c ific ity
Sensitivity and specificity of the different response scores Sensitivity of DAS28 at the same specificity level
Specificity (%) Sensitivity (%) Sensitivity (%) According DAS28 
score
No moderate DAS response 83.3 46.7 67.5 4.8
No good DAS response 42.4 96.3 97.3 3.1
No ACR20 response 64.2 69.6 80.0 4.0
No ACR50 response 33.6 85.9 97.5 2.9
DAS, disease activity score.
DAS28 (0.840) at week 22. Additionally, when we fitted a 
logistic regression model w ith the decision to give a dose 
increase as a dependent variable and D AS28 at week 22, 
delta D A S28 0 -2 2  and delta D A S28 6 -2 2  as covariates, only 
DAS28 at week 22 was a significant variable in the model.
Sim ilar analyses were performed for the other variables. The 
A U C  of the differences between weeks 0 -2 2 , weeks 6 -2 2  
and weeks 1 4 -2 2  of the other variables were all less than 
0 .700 (data not shown). These analyses indicate that, 
although the differences in disease activity over time are sta­
tistically significant, those differences over time are not impor-
R1G66
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F igure  1
Plot of the mean scores over time. Act, activity; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; SJC, swollen joint 
count; TJC, tender joint count; pt, patient; Phys, physician; SQRT, variable normalized by taking the squared root; ln, variable normalized by taking 
the natural logarithm; VAS, visual analogue scale.
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tant enough to incorporate in a model to discrim inate the 
physician's decision.
Building a model to discriminate the physician’s decision 
to give a dose increase
The first three analyses (ranking of continuous variables, eval­
uation of the response scores and effects of change of scores 
over time on the physician's decision) allowed us to narrow the 
selection of variables fo r the model by elim inating variables 
that are already incorporated into the D AS28 (or are highly 
related to them such as CRP and 68 tender jo int and 66 sw o l­
len jo int count) and taking into account only those variables at 
week 22. This resulted in the fo llow ing list: DAS28, HAQ, phy­
sician global VAS, patient pain VAS, patient fatigue VAS and 
the scores of the SF36 questionnaire at week 22. W e 
screened those variables using forward and backward elim ina­
tion in a logistic regression model and by the stepw ise W ilk 's 
lambda method. The probability scores of the logistic regres­
sion and discrim inant scores we thus obtained were com ­
pared using R O C  curve analysis. The model w ith the highest 
A U C  was a model from discrim inant analysis w ith the fo llow ing 
variables (and standardized canonical discrim inant function 
coeffic ients): D A S28 week 22 (0.863), physician global VAS 
(0.796), patient pain VAS (0.735), and physical functioning (­
0.227). The discrim inant score of this model had an A U C  of 
0 .870 (95%  CI: 0 .8 2 8 -0 .9 1 2 ) w ith a sensitivity at the 95%  
specific ity level of 45 .5%  (95%  CI: 3 8 .7 -5 0 .3 ).
F igure  2
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Validation of the DAS28 score and coefficients (see text). ESR, erythro­
cyte sedimentation rate; VAS, visual analogue scale.
Evaluation of the discriminant score of the variables of 
DAS28
To validate the score and coeffic ients of the DAS28, we cal­
culated a discrim inant function using the (normalized) varia­
bles of the D A S28 score: 28  tender and swollen jo int count, 
ESR and patient global VAS. A fte r rescaling, we obtained the 
fo llow ing discrim inant coeffic ients: 0 .52 fo r 28  tender jo int 
count (28TJC), 0 .28  for 28 swollen jo int count (28SJC), 0.56 
for ESR and 0 .025 for patient disease activity. This d iscrim i­
nant score had an A U C  of 0 .844  (0 .7 9 7 -0 .8 9 1 ) and a sensi­
tivity at the 95%  specific ity level of 43 .8%  (95%  CI: 38 .1 ­
49.2), which is equal to the D AS28 at week 22. The Pearson's 
correlation coeffic ient between this discrim inant score and the 
D AS28 was 0 .986 (Fig. 2). W e also performed logistic regres­
sion w ith sim ilar results (data not shown).
Comparison with the other DAS scores and SDAI/CDAI
Since different alternative m ethods are available to calculate 
the DAS scores (Table 1), we additionally evaluated the prop­
erties of those alternative scores. W e also evaluated the SDAI 
and CDAI [8,9], after normalization, by taking the squared root. 
The Pearson's correlation coeffic ient of those alternative 
scores w ith the D AS28 at week 22 was 0 .982  for the DAS28- 
3, 0 .952  fo r the DAS28-CRP, 0 .928  for the DAS28-CRP-3, 
0 .914  for the SDAI and 0 .893  for the CDAI. The A U C  and sen­
sitivity at the 95%  specific ity level are shown in Table 1 and 
indicate that all those alternative scores perform similarly or 
slightly worse than the original DAS28.
Detailed ROC curve analysis of the DAS28
W e plotted the R O C  curve of the D A S28 in Fig. 3 and listed 
sensitivities and specific ities in Table 4 . Also, predictive values 
and the accuracies of classification in function of the different 
D AS28 cut-offs are shown in Table 4 . Beneath a cut-off of 3.2, 
we found a high predictive value for continuing the current 
dose as a measure of good response. The maximal accuracy 
of 84%  could be found at a cut-off of 5.5.
Discussion
The aim of the present analyses was to evaluate which single 
or com posite variables, com bined in a model, could 
discrim inate the treating rheum atologist's decision to give a 
dose increase of infliximab to RA patients not optimally 
responding to an indicated dose of 3 mg infliximab every 8 
weeks. S ince different variables on different time points were 
available, we started to rank the continuous variables based on 
the A U C  of R O C  curves and sensitivities at the 95%  specifi­
city level. This strategy has previously been proposed for 
microarray data [1 7]. The calculation of sensitivities at the 
95%  specific ity level is important in order not to overlook some 
variables w ith a relative small A U C  but w ith a high specific ity 
[16]. So, both m ethods ranked the D AS28 at week 22 as the 
variable which best discrim inates the decision to give a dose 
increase. In a second and third analysis, we looked at whether 
response scores and differences in disease activity over time
R1068
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Table  4
P erfo rm ance a t d iffe re n t cu t-o ffs  o f DAS28 a t w e e k  22 fo r  dose  increase
DAS cut-off Sensitivity Specificity PPV NPV Accuracy
2.0 0.99 0.13 0.23 0.98 0.31
2.5 0.99 0.22 0.25 0.99 0.38
2.6 0.99 0.26 0.26 0.99 0.41
3.0 0.98 0.38 0.29 0.98 0.50
3.2 0.96 0.46 0.32 0.98 0.57
4.0 0.79 0.66 0.38 0.92 0.68
4.5 0.76 0.77 0.47 0.92 0.77
5.0 0.58 0.87 0.55 0.89 0.81
5.1 0.53 0.88 0.55 0.88 0.81
5.5 0.43 0.95 0.69 0.86 0.84
6.0 0.34 0.97 0.73 0.85 0.83
6.5 0.19 0.98 0.72 0.82 0.81
DAS, disease activity score; PPV, positive predictive value (predictive value to give a dose increase as a measure of insufficient response); NPV, 
negative predictive value (predictive value to continue on the current dose as a measure of good response); PPV, NPV and accuracy were 
calculated using the following formulae:
a) PPV =
sensitivity * a _ priori _ chance
sensitivity * a _ priori _ chance + (1 -  specificity) *(1 -  a _ priori _ chance) 
specificity *(1 -  a _ priori _ chance)
b) NPV = ---------------
specificity *(1 -  a_priori_ chance) + (1 -  sensitivity)* a_ priori_ chance)
c) Accuracy =  sensitivity* a_priori_chance + specificity* (1-a_priori_chance)
The a priori chance is given by the percentage of patients that need a dose increase as a measure of insufficient response.
could give additional information to discrim inate the rheuma­
to log ist's  decision. Those analyses indicated that variables, 
including differences over time, seem to be less important than 
the momentary remaining disease activity at week 22, to d is­
crim inate the rheum atologist's decision.
A fter the prior selection of variables, based on the find ings of 
the previous steps, we built the final model to discrim inate the 
rheum atologist's decision, which was only slightly better than 
the DAS28. W e think that the small gain in discrim inative prop­
erties in comparison w ith the D AS28 is not enough to accept 
the increased complexity of this model. Moreover, in contrast 
to the DAS28, this model included the physician's global 
assessment of disease activity (VAS), which is investigator- 
dependent and has the draw-back that it cannot be calculated 
by a study nurse. All four analyses together indicated that the 
DAS28 is an important variable fo r evaluating insufficient 
response to infliximab therapy (especially in daily practice) and 
that this variable can only slightly be improved by adding sup­
plemental variables.
DAS was developed in the early 1990s [19,20] and later on, 
it was transformed into the D AS28 [7] in an era when therapy 
w ith biologicals was not yet available. In those initial studies, 
patients were scored by the same tw o independent nurses
and the decision to change disease-modifying antirheumatic 
drug (DMARD) therapy during a fo llow -up period of up to 3 
years was considered as a measure of insufficient response 
[20]. The present study is a m ulti-center study where patients 
were scored by the treating physician and the decision to give 
a dose increase of infliximab could happen only at one time 
point. This difference in study design and therapy may explain 
why in the present study the A U C  of D A S28 is smaller than in 
other studies (AUC =  0 .840  versus 0.933) [21]. Therefore, it 
is remarkable that despite those differences in study design, 
we could calculate a discrim inant function (in the fifth analysis) 
that correlated so well w ith the D A S 28 by using the 28SJC, 
28TJC, ESR and patient disease activity VAS as independent 
variables and the physician's decision as a grouping variable. 
Not only the discrim inant scores, but also the coeffic ients of 
this discrim inant function were quite similar to the coefficients 
of the DAS28, indicating the robustness of the scores and 
coeffic ients of the D AS28 score.
In another, final analysis, we evaluated the alternative DAS 
scores and the squared root transformed SDAI and CDAI. All 
those alternative scores have a slightly worse A U C  than the 
original DAS28, but seem good enough to be useful when 
some other variables are not available. W e think the use of the 
D AS28 is feasible and time-effective using a preprogrammed
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calculator, spreadsheet or web-based calculator [11]. The 
unique characteristics of the DAS score make it a useful meas­
ure in a lot of applications. D AS28 as a continuous variable is 
a sensitive tool fo r measuring response to treatm ent in rand­
omized contro lled trials and facilitates the use of more complex 
statistical m ethods that can handle repeated measures over 
different time points [22-24].
O ther studies dem onstrated that a low DAS is an important 
prognostic factor of persistent remission and that DAS corre­
lates w ith radiological progression [25 ,26]. DAS may also be 
a useful parameter in daily clinical practice as a treatm ent goal 
and to evaluate the actual disease activity (which cannot be 
assessed by the categorical response scores) [27-31]. O ur 
find ings that the physician's decision to give a dose increase 
can best be modeled by a combination of measurements of 
remaining/momentary disease activity, represented by the 
DAS28 does not reduce the value of the response scores 
such as A C R  response or DAS response scores. Indeed, 
those scores are important for measuring differences over 
time as a measure of global treatment effects in clinical trials 
[12,13] but, as demonstrated by the present study, are not 
useful for evaluating the momentary disease activity in a single 
patient, which is important in daily practice. The continuous 
properties of the D AS28 score provide the additional opportu­
nity fo r a cut-off, which can be chosen as a function of the pur­
pose. Interestingly, we found a high predictive value for 
continuing the current dose as a measure of good response 
below a cut-off of 3.2. It is noteworthy that a DAS score of 3.2 
is an important threshold fo r a good DAS response according 
to the EULAR criteria [12]. In contrast, fo r classification pur­
pose, a higher cut-off (5.5) is more appropriate since this level
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displayed the highest accuracy. One should be aware that the 
displayed predictive values and accuracies may be highly influ­
enced by the prevalence of insufficient response, reflected by 
the need for a dose increase, which was 21 .5%  in the present 
study. A  lower a p rio ri chance of the need for a dose increase 
may increase the accuracy of DAS (given the fixed cut-off of 
5.5) and vice versa. Indeed, at a cut-off w ith a high specificity, 
the accuracy will increase when the a p rio r i chance decreases 
(applying formula c given in the legend to Table 4 ).
Conclusion
The results of the present analyses indicate that the momen­
tary D AS28 as a continuous com posite index correlates best 
w ith the decision to give a dose increase of infliximab, which is 
a measure of insufficient response. The discrim inative charac­
teristics of the DAS could be slightly improved by the use of 
supplemental variables, although this results in the disadvan­
tage of a more complex model and calculations. This study 
also dem onstrates the robustness of the scores and coeffi­
cients of the D AS28 in a cohort of RA patients under infliximab 
therapy and therefore validates the D AS28 as a measure of 
disease activity in patients under treatment w ith biologicals.
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